Publications by authors named "Leah Isakov"

Claim this Profile
C
Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
Brandon J Essink, Wim Vermeulen, Coralie Andrade, Richard de Rooij, Leah Isakov

Vaccine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
Brandon J Essink, Wim Vermeulen, Coralie Andrade, Richard de Rooij, Leah Isakov

Vaccine· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
Airi Poder, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Leah Isakov

Vaccines (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates.
Donald A Berry, Scott Berry, Peter Hale, Leah Isakov, Andrew W Lo

PLoS One· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.
Marten Heeringa, Brett Leav, Igor Smolenov, Giuseppe Palladino, Leah Isakov

J Clin Microbiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Timo Vesikari, Judith Kirstein, Grace Devota Go, Brett Leav, Mary Ellen Ruzycky, Leah Isakov

Lancet Respir Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.
Steven Simoens, Ira Jacobs, Robert Popovian, Leah Isakov, Lesley G Shane

Pharmacoeconomics· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical Primer on Biosimilar Clinical Development.
Leah Isakov, Bo Jin, Ira Allen Jacobs

Am J Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
Ira Jacobs, Danielle Petersel, Leah Isakov, Sadiq Lula, K Lea Sewell

BioDrugs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
Christopher Wood, Pramod Srivastava, Ronald Bukowski, Louis Lacombe, Andrei I Gorelov, Leah Isakov

Lancet· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis